Krystal Biotech, Inc. Common Stock (KRYS) is a publicly traded Healthcare sector company. As of August 25, 2026, KRYS trades at $342.62 with a market cap of $10.26B and a P/E ratio of 40.95. KRYS moved -1.45% today. Year to date, KRYS is +38.61%; over the trailing twelve months it is +127.08%. Its 52-week range spans $122.80 to $382.54. Analyst consensus is strong buy with an average price target of $402.67. Rallies surfaces KRYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks KRYS insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $342.62 |
| Market Cap | $10.26B |
| P/E Ratio | 40.95 |
| EPS | $8.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $382.54 |
| 52-Week Low | $122.80 |
| Volume | 163.21K |
| Avg Volume | 0 |
| Revenue (TTM) | $440.48M |
| Net Income | $241.47M |
| Gross Margin | 0.00% |
8 analysts cover KRYS: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $402.67.